| ZHANG, YANQIAO |
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT06432296: Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody |
|
|
| Recruiting | 3 | 270 | RoW | M701, paracentesis | Wuhan YZY Biopharma Co., Ltd. | Malignant Ascites | 08/25 | 11/25 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001 | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 12/27 | | |
NCT06512428: A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 138 | RoW | simmitinib plus irinotecan liposome, irinotecan liposome, irinotecan | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Advanced Esophageal Squamous Cell Carcinoma | 01/26 | 01/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06192680: Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 63 | NA | Liposomal irinotecan, nal-IRI, Capecitabine, Xeloda, Bevacizumab, Avastin | Harbin Medical University | Colorectal Cancer | 11/25 | 09/26 | | |
AK104-IIT-041, NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur | Harbin Medical University | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 01/27 | 03/27 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 80 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 10/24 | 11/24 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT04298320: A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457） |
|
|
| Not yet recruiting | 1/2 | 40 | NA | SHR-1210, AIN 457 | Yanqiao Zhang | Colorectal Cancer | 02/22 | 02/23 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT05038150: Study of SGN1 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 70 | US, RoW | SGN1, SalMet-Vec | Guangzhou Sinogen Pharmaceutical Co., Ltd, ClinChoice Enterprise Management (Shanghai) Limited, Parexel | Advanced Solid Tumor | 01/28 | 08/28 | | |
NCT05846867: Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 72 | RoW | AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate, Fluorouracil | Akeso | Colorectal Cancer | 05/24 | 07/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
NCT06513455: Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer |
|
|
| Not yet recruiting | 1/2 | 132 | NA | Irinotecan liposome（40mg/m2）, Irinotecan Liposome, Nab-paclitaxel, Albumin Paclitaxel, Gemcitabine, Gemcitabine injection, Irinotecan Liposome（60mg/m2） | Harbin Medical University | Pancreatic Cancer | 06/27 | 12/27 | | |
| Active, not recruiting | 1/2 | 206 | RoW | LM-302 Injection | LaNova Medicines Zhejiang Co., Ltd. | Advanced Solid Tumor | 03/25 | 06/25 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT05470933: A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 7 | RoW | WJ01075 | Suzhou Junjing BioSciences Co., Ltd. | Advanced Solid Tumors | 04/23 | 04/23 | | |
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
NCT05554666: A Study of ASKG315 in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 56 | RoW | ASKG315 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/23 | 10/24 | | |
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/25 | 12/25 | | |
| Recruiting | 1 | 250 | RoW | QLC1101 | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor | 05/26 | 04/27 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
NCT05277454: Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT |
|
|
| Recruiting | 1 | 113 | RoW | HMPL-653 | Hutchison Medipharma Limited | Advanced Malignant Solid Tumors, TGCT | 06/24 | 04/25 | | |
| Recruiting | 1 | 37 | RoW | ET0111 | Etern BioPharma (Shanghai) Co., Ltd | Advanced Solid Tumor | 12/24 | 05/25 | | |
| Recruiting | 1 | 50 | RoW | TR128 | Tarapeutics Science Inc. | Advanced Solid Tumor | 08/25 | 12/25 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
NCT05407909: To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 176 | RoW | SYHX2001 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced or Metastatic Solid Tumors | 01/26 | 01/26 | | |
NCT04684095: The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 338 | RoW | electronic patient report outcome | Harbin Medical University | Colorectal Cancer Metastatic, Cancer | 02/22 | 06/24 | | |
| Pang, Da |
NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer |
|
|
| Recruiting | 3 | 844 | RoW | Tamoxifen, Tamoxifen citrate, Toremifene, fareston | Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University | Breast Cancer Female | 12/25 | 12/25 | | |
| Ma, Jianqun |
KEYSTONE-002, NCT04807673: Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC |
|
|
| Recruiting | 3 | 342 | RoW | Pembrolizumab, Keytruda, Paclitaxel, Cisplatin, neoadjuvant chemoradiotherapy | Tianjin Medical University Cancer Institute and Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Ruijin Hospital, Hebei Medical University Fourth Hospital, Harbin Medical University, Liaoning Tumor Hospital & Institute, Shanxi Province Cancer Hospital, Shandong Jining No.1 People's Hospital, Weifang People's Hospital, Tianjin Medical University General Hospital, Shandong Provincial Hospital | Esophageal Squamous Cell Carcinoma | 12/23 | 05/28 | | |
NCT06508229: Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC |
|
|
| Not yet recruiting | 2 | 65 | NA | Adebrelimab, SHR-1316, albumin paclitaxel, Injectable paclitaxel (albumin bound), Nedaplatin, Nedaplatin for injection | Harbin Medical University | Esophageal Squamous Cell Carcinoma | 05/27 | 05/28 | | |
